Skip to main content

Peptide Pipeline Index

Which peptides are moving through clinical research. The index counts the running studies per peptide in the public register ClinicalTrials.gov and weights them by phase.

Study activity is not a statement about efficacy or safety. The index counts register entries and does not assess any result.

Ranking

Register data as of November 16, 2026

Peptides by pipeline points, with running studies per phase and the change over twelve months
#PeptidePoints12 months
1SemaglutideP1 26 · P2 63 · P3 64 · P4 66Studies (520)804+264
2TirzepatideP1 15 · P2 51 · P3 26 · P4 37Studies (205)443+159
3TriptorelinP1 0 · P2 11 · P3 18 · P4 3Studies (137)112+20
4OxytocinP1 6 · P2 17 · P3 4 · P4 9Studies (376)110+18
5MazdutideP1 0 · P2 6 · P3 6 · P4 5Studies (37)66+38
6HCGP1 2 · P2 4 · P3 6 · P4 4Studies (159)58+19
7HGHP1 1 · P2 8 · P3 8 · P4 1Studies (200)55+22
8CagrilintideP1 7 · P2 0 · P3 10 · P4 0Studies (50)47−10
9EloralintideP1 8 · P2 3 · P3 8 · P4 0Studies (26)46+38
10RetatrutideP1 1 · P2 1 · P3 9 · P4 0Studies (33)39−7
11TeriparatideP1 0 · P2 1 · P3 1 · P4 5Studies (120)36±0
12SurvodutideP1 3 · P2 1 · P3 6 · P4 0Studies (35)29−9
13Thymosin Alpha 1P1 1 · P2 8 · P3 1 · P4 1Studies (43)27+10
14CagriSemaP1 1 · P2 0 · P3 5 · P4 0Studies (12)21+13
15CerebrolysinP1 0 · P2 3 · P3 0 · P4 2Studies (31)18±0
16HMGP1 0 · P2 1 · P3 2 · P4 1Studies (52)16+10
17CBL-514P1 0 · P2 2 · P3 3 · P4 0Studies (16)16+10
18SS-31P1 1 · P2 1 · P3 1 · P4 1Studies (30)13+9
19GLP-2P1 0 · P2 1 · P3 1 · P4 0Studies (37)6+2
20TesamorelinP1 0 · P2 3 · P3 0 · P4 0Studies (16)6+2
21GonadorelinP1 2 · P2 0 · P3 1 · P4 0Studies (6)6−2
22KisspeptinP1 1 · P2 2 · P3 0 · P4 0Studies (19)5±0
23Melanotan 1P1 0 · P2 0 · P3 1 · P4 0Studies (22)4±0
24TB-500P1 0 · P2 2 · P3 0 · P4 0Studies (14)4±0
25ACTH 1-39P1 0 · P2 0 · P3 1 · P4 0Studies (1)4±0
26BPC-157P1 1 · P2 1 · P3 0 · P4 0Studies (3)3+3
27PT-141P1 0 · P2 1 · P3 0 · P4 0Studies (10)2±0
28VIPP1 0 · P2 1 · P3 0 · P4 0Studies (9)2±0
29Melanotan 2P1 0 · P2 1 · P3 0 · P4 0Studies (1)2+2
30GHK-CuP1 0 · P2 1 · P3 0 · P4 0Studies (1)2+2
31MOTS-CP1 0 · P2 1 · P3 0 · P4 0Studies (1)2+2
32TesofensineP1 0 · P2 0 · P3 0 · P4 0Studies (12)0±0
33LarazotideP1 0 · P2 0 · P3 0 · P4 0Studies (10)0−2
34MK-677 (Ibutamoren)P1 0 · P2 0 · P3 0 · P4 0Studies (6)0±0
35ARA 290P1 0 · P2 0 · P3 0 · P4 0Studies (4)0±0
36TRH (Thyrotropin-Releasing Hormone)P1 0 · P2 0 · P3 0 · P4 0Studies (4)0±0
37ACE-031P1 0 · P2 0 · P3 0 · P4 0Studies (4)0±0
38AICARP1 0 · P2 0 · P3 0 · P4 0Studies (3)0±0
39IpamorelinP1 0 · P2 0 · P3 0 · P4 0Studies (2)0±0
40LL-37P1 0 · P2 0 · P3 0 · P4 0Studies (2)0±0
41ArgirelineP1 0 · P2 0 · P3 0 · P4 0Studies (1)0±0
42CJC-1295 DACP1 0 · P2 0 · P3 0 · P4 0Studies (1)0±0
43HEP-1P1 0 · P2 0 · P3 0 · P4 0Studies (1)0±0
44TP508 (Chrysalin)P1 0 · P2 0 · P3 0 · P4 0Studies (1)0±0

Points: running studies weighted by phase. 12 months: change in points against the state 12 months earlier. Phase columns: number of running studies. Studies: all register entries with a phase, ended ones included.

Method

  • The source is ClinicalTrials.gov, the public study register of the U.S. National Library of Medicine. ChemVerify reads it once a week through the register's open interface.
  • A study counts for a peptide only when the substance is listed among the study's interventions, under its name, its non-proprietary name or a development code. A mention in the title or the description is not enough. Placebo arms and diagnostic uses do not count.
  • Only interventional studies with a stated phase are counted. Observational studies and studies without a phase are left out.
  • A study is running when the register lists it as “Not yet recruiting”, “Recruiting”, “Enrolling by invitation” or “Active, not recruiting”.
  • Each running study scores by its highest phase: Phase 1 scores 1, Phase 2 scores 2, Phase 3 scores 4, Phase 4 scores 6. Early Phase 1 counts as Phase 1; a combined phase counts as the higher one.
  • The change compares today's points with the points 12 months earlier, reconstructed from the dates in the register: a study counts for the earlier day if it was already posted and had not yet ended. Suspended and withdrawn studies and studies of unknown status count on neither day, because the register does not date them.
  • The register is incomplete: studies entered only in other registers are missing, and sponsors update entries with delay. Blends, solvents and catalog entries that are not a single substance are not searched.
  • The index has no influence on the price comparison, on the order of vendors or on the ChemVerified seal, and it cannot be bought.

Open ClinicalTrials.gov

For laboratory research use only. Not for human consumption. Must be 18+.